Nevertheless, a recent study proposed that any ARID1A loss—irrespective of the percentage area of the tumor affected (heterogeneous/clonal/diffuse)—may be associated with specific clinicopathological or molecular features [76]. Here, ARID1A is linked to neoplasm.